Table 4. Multivariate Cox proportional hazards model analysis of OS in individuals with NSCLC.
| Variables | P value | HR | 95% CI |
|---|---|---|---|
| Adjuvant therapy (chemo-radiotherapy, none) | 0.129 | 2.196 | 0.796–6.085 |
| COA-NLR (0, 1, 2) | <0.001 | 1.952 | 1.367–2.647 |
| GPS (0, 1, 2) | 0.912 | 0.961 | 0.584–1.618 |
| WBC, 109/L (≥6.6, <6.6) | 0.131 | 1.991 | 0.814–4.859 |
| Neutrophil, 109/L (≥3.7, <3.7) | 0.165 | 2.043 | 0.726–6.551 |
| Lymph, 109/L (≥2.1, <2.1) | 0.045 | 0.486 | 0.260–0.985 |
| PLT, 109/L (≥200, <200) | 0.007 | 1.878 | 1.403–3.970 |
| ALT, U/L (≥20, <20) | 0.216 | 1.362 | 0.832–2.265 |
| Glucose, mmol/L (≥6, <6) | 0.018 | 1.450 | 1.125–3.443 |
| Pathologic N stage (N0, N1, N2, N3) | 0.088 | 1.743 | 0.923–3.213 |
| Pathologic T stage (T1, T2, T3, T4) | 0.261 | 1.574 | 0.747–2.926 |
| Metastasis (no, yes) | 0.267 | 1.704 | 0.596–6.470 |
| TNM status (1, 2, 3, 4) | <0.001 | 1.852 | 1.523–2.547 |
OS, overall survival; NSCLC, non-small cell lung cancer; HR, hazard ratio; CI, confidence interval; COA-NLR, combination of albumin concentration and neutrophil-to-lymphocyte ratio; GPS, Glasgow prognostic score; WBC, white blood cell; PLT, platelet; ALT, alanine transaminase; TNM, tumor-node-metastasis.